Fulgent Genetics, Inc. FLGT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Laboratory Services | $71.05M-14.4% | $83.03M-1.1% | $83.93M+2.6% | $81.8M+11.4% | $73.46M-3.6% | |
| Therapeutic Development | $87K-71.8% | $309K+124% | $138K— | $0— | $0— | |
| Operating Income by Business | ||||||
| Laboratory Services | -$15.22M-264% | -$4.18M-268% | $2.49M+188% | -$2.81M+6.5% | -$3M— | |
| Therapeutic Development | -$4.46M+5.6% | -$4.72M+21.4% | -$6M-23.1% | -$4.88M-14.7% | -$4.25M+4.3% | |
| Cost Of Revenue by Business | ||||||
| Laboratory Services | $48.18M-1.9% | $49.14M+4.9% | $46.86M+2.7% | $45.63M+5.3% | $43.34M+1.9% | |
| Therapeutic Development | $8K+60.0% | $5K— | $0— | $0— | $0— | |
| Interest Expense Nonoperating by Business | ||||||
| Laboratory Services | $17K+6.3% | $16K-42.9% | $28K+64.7% | $17K+21.4% | $14K— | |
| Therapeutic Development | $0— | $0— | $0— | $0— | $0— | |
| Finite Lived Intangible Assets Gross by Business | ||||||
| Laboratory Services | $105.15M+26.5% | $83.14M0.0% | $83.12M0.0% | $83.11M0.0% | $83.09M0.0% | |
| Therapeutic Development | $2.3M0.0% | $2.3M0.0% | $2.3M— | —— | —— | |
| Finite Lived Intangible Assets Net by Business | ||||||
| Laboratory Services | $83.3M+33.2% | $62.56M-3.0% | $64.5M-3.0% | $66.47M-2.8% | $68.42M-2.8% | |
| Therapeutic Development | $70.69M0.0% | $70.73M+3,018% | $2.27M— | —— | —— | |
| Selling And Marketing Expense by Business | ||||||
| Laboratory Services | $11.58M+12.5% | $10.29M-5.6% | $10.91M-5.8% | $11.58M+52.8% | $7.58M-12.1% | |
| Therapeutic Development | $0-100% | $5K— | $0— | $0— | $0— | |
| Total Assets by Business | ||||||
| Laboratory Services | $1.05B-4.5% | $1.1B+1.2% | $1.08B-2.5% | $1.11B-0.5% | $1.12B-1.3% | |
| Therapeutic Development | $109.14M-6.8% | $117.15M-10.7% | $131.14M+47.9% | $88.66M-0.3% | $88.9M+0.1% | |
| Investment Income Interest by Business | ||||||
| Laboratory Services | $8.65M+24.7% | $6.94M-11.9% | $7.87M-2.7% | $8.09M+0.9% | $8.02M-1.3% | |
| Therapeutic Development | $0— | $0— | $0— | $0— | $0— | |
| Research And Development Expense by Business | ||||||
| Laboratory Services | $6.46M+5.6% | $6.12M+18.9% | $5.15M-5.2% | $5.44M+10.2% | $4.93M+8.2% | |
| Therapeutic Development | $4.18M-14.4% | $4.88M-10.7% | $5.46M+16.1% | $4.71M+17.9% | $3.99M-3.8% | |
| General And Administrative Expense by Business | ||||||
| Laboratory Services | $20.05M-7.4% | $21.66M+16.9% | $18.53M-15.7% | $21.97M+6.5% | $20.62M+4.0% | |
| Therapeutic Development | $357K+157% | $139K-79.5% | $678K+299% | $170K-34.9% | $261K-10.6% | |
| D&A by Business | ||||||
| Laboratory Services | $5.86M-2.1% | $5.98M+0.9% | $5.93M+0.7% | $5.89M+2.3% | $5.76M-4.4% | |
| Therapeutic Development | $143K+8.3% | $132K+20.0% | $110K-33.3% | $165K+0.6% | $164K-4.1% | |
| Allocated Share Based Compensation Expense by Business | ||||||
| Laboratory Services | $7.64M+4.9% | $7.29M-5.6% | $7.72M-4.0% | $8.03M-5.8% | $8.53M-0.4% | |
| Therapeutic Development | $2.25M+13.0% | $1.99M-0.5% | $2M-0.2% | $2.01M-0.6% | $2.02M+9.7% | |
| Finite Lived Intangible Assets Accumulated Amortization by Business | ||||||
| Laboratory Services | $27.28M+6.4% | $25.63M+6.9% | $23.99M+7.3% | $22.35M+7.9% | $20.71M+8.6% | |
| Therapeutic Development | $96K+50.0% | $64K+100% | $32K— | —— | —— | |
| Goodwill by Business | ||||||
| Laboratory Services | $31.38M— | —— | —— | —— | —— | |
| Therapeutic Development | $22.35M-10.9% | $25.08M0.0% | $25.08M+13.5% | $22.1M0.0% | $22.1M+0.2% | |
| Revenue by Geography | ||||||
| Non Us | $6.03M-28.4% | $8.43M+30.4% | $6.46M+15.5% | $5.6M-0.7% | $5.64M-8.1% | |
| Other Countries | $3.47M-5.2% | $3.67M+10.0% | $3.33M+4.5% | $3.19M+5.4% | $3.03M+5.7% | |
| PP&E (Net) by Geography | ||||||
| Non Us | $6.16M-2.3% | $6.3M-1.6% | $6.4M-2.3% | $6.56M+1.5% | $6.46M-1.5% | |
| Other Countries | $1.55M-3.5% | $1.61M-4.7% | $1.69M-3.6% | $1.75M-0.4% | $1.76M-9.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Fulgent Genetics, Inc. break its business down?
- Fulgent Genetics, Inc. (FLGT) reports revenue by business across 2 parts — Laboratory Services and Therapeutic Development. Each is extracted from the segment footnotes and tracked over time.
- Where does Fulgent Genetics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Fulgent Genetics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
